taken 21 days after primary immunization. Each bar represents the mean of 3 experiments from pooled vaginal mucosal samples.--

On page 34, line 3, before the sentence beginning "The neutralization" please insert the following paragraph:

--Figures 5a and 5b show results from female BALB/c mice in groups of 5 immunized on days 0 and 7 by intranasal or intravaginal delivery of CAP, HSV-2 or HSV-2+CAP. ELISA titers of IgG HSV-2 antibodies were measured serially. Each bar represents the group mean of the end-point dilution titer for mice immunized intranasally or intravaginally.--

A 2

On page 34, line 25, before the sentence beginning "The current" please insert the following paragraph:

--Figures 6a and 6b show results from BALB/c mice (n=5/group) challenged intravaginally with 10^6 PFU of HSV-2 50 days after primary immunization. Clinical pathology was scored on a 5-point scale; 0, no apparent infection; 1, slight redness of external vagina; 2, severe redness and swelling of external vagina; 3, genital ulceration with severe redness, swelling, and hair loss of genital and surrounding tissue; 4, severe ulceration of genital and surrounding tissue and paralysis; 5, Death.--

A 3

On page 35, line 30, after the sentence ending "lethality" please insert the following sentence:

--(For Figures 7a-7c, serum and mouth wash samples were collected at 7 weeks after first immunization and pooled from 5 mice and analyzed in triplicate.)--

A4

On page 36, line 19, after the sentence ending "eye pressure." please insert the following sentence:

--Figure 8 shows results from rabbits treated with 225ug CAP, 1% 7-OH-DPAT, and 225ug CAP + 1% 7-OH-DPAT respectively. Each experimental group contained two rabbits.--

A5